Arbutus Biopharma Corporation · NASDAQ:ABUS

Arbutus Biopharma — Investor Presentation (January 2021)

25 slides from Arbutus Biopharma's investor presentation, Jan 25, 2021

  1. Slide 1: Corporate Presentation January 2021

    Corporate Presentation January 2021 NASDAQ: ABUS www.arbutusbio.com

  2. Slide 2: Forward-Looking Statements

    NASDAQ: ABUS www.arbutusbio.com Forward - Looking Statements 2 This presentation contains forward - looking statements within the meaning of the U . S . Private Securities Litigation Reform Act of 1995 and Canadian securities laws . All statements that are not historical facts are hereby identified

  3. Slide 3: Investment Highlights

    NASDAQ: ABUS www.arbutusbio.com Investment Highlights Therapeutic focus – curing chronic Hepatitis B Virus (HBV) Infection 3 HCV: Hepatitis C Virus | HIV Human Immunodeficiency Virus Significant Unmet Medical Need in HBV Undetectable HBV DNA and HBsAg delivered through finite duration treatment with

  4. Slide 4: Proven Leadership Team

    NASDAQ: ABUS www.arbutusbio.com NASDAQ: ABUS www.arbutusbio.com Proven Leadership Team 4 Successful track records in the discovery, development, and commercialization of multiple antivirals including sofosbuvir, etravirine, rilpivirine , telaprevir and simeprevir William H. Collier Chief Development

  5. Slide 5: HBV Presents a Significant Unmet Medical Need

    NASDAQ: ABUS www.arbutusbio.com Sources : Global Hepatitis Report and Hepatitis B Fact Sheet, WHO (2017) http://www.who.int/mediacentre/factsheets/fs204/en/ Kowdley et al. Hepatology (2012) Prevalence of Chronic Hepatitis B Among Foreign - Born Persons Living in the US by Country of Origin HBV Prese

  6. Slide 6: Significant Opportunity to Improve HBV Cure Rates

    NASDAQ: ABUS www.arbutusbio.com New HBV Therapies rate of Undetectable HBV DNA rate of HBsAg Loss HIGHER CURES RATES SOC: Standard Of Care | HBsAg : HBV Surface Antigen | PegIFN : P egylated Interferon Source: EASL HBV Clinical Practice Guidelines, 2017 - Pegasys, PEG - Intron, Baraclude and Viread

  7. Slide 7: Compelling Growth Opportunity in the HBV Market

    NASDAQ: ABUS www.arbutusbio.com An HBV curative regimen would substantially increase diagnosis and treatment rates to unlock significant market growth opportunities. diagnosis Compelling Growth Opportunity in the HBV Market 7 SOC: Standard Of Care Source: Global Hepatitis Report and Hepatitis B Fact

  8. Slide 8: HBV Lifecycle Illustrates Key Points for Intervention

    NASDAQ: ABUS www.arbutusbio.com 3 2 1 2 HBV Lifecycle Illustrates Key Points for Intervention A combination of agents with complementary MOA is needed to cure HBV 1. Nucleoside Analogue 2. Capsid Inhibitor 3. RNAi & RNA Destabilizer NASDAQ: ABUS www.arbutusbio.com MOA: Mechanism of Action

  9. Slide 9: Keys to Therapeutic Success

    NASDAQ: ABUS www.arbutusbio.com 9 Block Replication ▪ NA ▪ Capsid Inhibitor ▪ RNAi ▪ RNA Destabilizer Reduce cccDNA Pool ▪ Capsid Inhibitor Block HBsAg ▪ RNAi ▪ RNA Destabilizer Immuno - modulation ▪ PD - L1 Inhibitor ▪ Interferon Leading to an HBV CURE Keys to Therapeutic Success MOA: Mechanism of

  10. Slide 10: Arbutus HBV Pipeline

    NASDAQ: ABUS www.arbutusbio.com Arbutus HBV Pipeline 10 Phase I Lead Optimization CTA/I ND Enabling Healthy Subjects HBV Subjects Phase II HBsAg Reduction RNAi AB - 729 HBV RNA Destabilizers Next Gen HBV DNA Suppression Capsid Inhibitor AB - 836 Immune Reawakening PD - L1 1st gen

  11. Slide 11: RNAi Therapeutic

    NASDAQ: ABUS www.arbutusbio.com AB - 729 RNAi Therapeutic 11 Proprietary GalNAc - conjugate delivery technology provides liver targeting and enables subcutaneous dosing Single trigger RNAi agent targeting all HBV transcripts Inhibits HBV replication and lowers all HBV antigens Pan - genotypic activi

  12. Slide 12: Study Design: Part 1 Single Ascending Dose

    NASDAQ: ABUS www.arbutusbio.com Cohort J: 90 mg Q12W HBV DNA - AB - 729 - 001 Study Part 1: Single Ascending Dose In Healthy Subjects Dose 1 (60 mg) Dose 2 (180 mg) Dose 3 (360 mg) (≥ Day 15 Safety) n=6; 4 active : 2 placebo n=6; 4 active : 2 placebo n=6; 4 active : 2 placebo Cohort A: 180 mg HBV DN

  13. Slide 13: Single Doses Result in Comparable Mean HBsAg Declines at Week 12

    NASDAQ: ABUS www.arbutusbio.com Single Doses of AB - 729 Result in Comparable Mean HBsAg Declines at Week 12 Followed by a Sustained Plateau Phase W e e k 1 2 -2.5 -2 -1.5 -1 -0.5 0 0.5 0 4 8 12 16 20 24 28 32 Cohort=A W e e k 1 2 -2.5 -2 -1.5 -1 -0.5 0 0.5 0 4 8 12 16 20 24 28 32 Cohort=C W e e k 1

  14. Slide 14: Repeat Dosing of 60 mg Every 4 Weeks Results in Continuous HBsAg Declines

    NASDAQ: ABUS www.arbutusbio.com W e e k 1 2 -2.5 -2 -1.5 -1 -0.5 0 0.5 0 4 8 12 16 20 24 AB-729 60 mg SD (N=6)* AB-729 90 mg SD (N=6)** AB-729 60 mg Q4W (N=7) Repeat Dosing of AB - 729 60 mg Every 4 Weeks Results in Continuous Mean HBsAg Declines Beyond Week 12 W e e k 1 2 -2 -1.5 -1 -0.5 0 0.5 0 4

  15. Slide 15: Repeat Dosing Every 8 Weeks Comparable to Every 4 Weeks

    NASDAQ: ABUS www.arbutusbio.com -2.5 -2 -1.5 -1 -0.5 0 0.5 0 4 8 12 16 20 24 Mean (SE) Week 20 : - 1.71 (0.18) Mean (SE) Week 24 : - 1.84 (0.16) Repeat Dosing of AB - 729 60 mg Every 8 Weeks Results in Comparable Mean HBsAg Declines to 60 mg Every 4 Weeks at Week 16 Mean (SE) Week 12: - 1.10 (0.15)

  16. Slide 16: Repeat Dosing Q8W Comparable to Q4W at Week 16

    NASDAQ: ABUS www.arbutusbio.com 16 Repeat D osing of AB - 729 60 mg Every 8 Weeks R esults in Comparable M ean HBsAg Declines to 60 mg E very 4 Weeks at Week 16 -2.5 -2 -1.5 -1 -0.5 0 0.5 0 4 8 12 16 20 24 AB-729 60 mg Q4W (N=7)* AB-729 60 mg Q8W (N=7)** Mean ( ± SE) HBsAg declines across repeat dos

  17. Slide 17: Single Dose Reduces HBsAg and HBV DNA in HBV DNA Positive CHB Subjects

    NASDAQ: ABUS www.arbutusbio.com AB - 729 90 mg Single Dose Reduces HBsAg and HBV DNA in HBV DNA Positive CHB subjects 2/5 HBsAg <100 IU/mL 0/5 HBsAg <10 IU/mL HBsAg (N=5) HBV DNA (N=5) Mean HBsAg decline is similar to HBV DNA negative CHB subjects Mean Individual W e e k 1 2 - 2.5 - 2 - 1.5 - 1 - 0.

  18. Slide 18: Safe and Well Tolerated After Single and Repeat Doses

    NASDAQ: ABUS www.arbutusbio.com AB - 729 Was Safe and Well Tolerated After Single and Repeat Doses ▪ No SAEs or discontinuations due to AEs ▪ No treatment - related Grade 3 or 4 AEs* ▪ No Grade 3 or 4 laboratory abnormalities* ▪ Grade 1 and Grade 2 ALT elevations have decreased with continued treatm

  19. Slide 19: Clinical Summary

    NASDAQ: ABUS www.arbutusbio.com 19 AB - 729 Clinical Summary Repeat 60 mg Q4W dosing with AB - 729 resulted in a continuous and robust mean HBsAg decline at week 24 ( - 1.84 log10 IU/mL, N=7) Repeat dosing of AB - 729 60 mg every 8 weeks results in comparable mean HBsAg declines relative to 60 mg ev

  20. Slide 20: Clinical Collaboration with Assembly Biosciences

    NASDAQ: ABUS www.arbutusbio.com NA: Nucleoside Analogue | HBeAg : HBV e Antigen AB - 729 Clinical Collaboration with Assembly Biosciences Provides accelerated AB - 729 combination proof of concept (POC) with a capsid inhibitor and NA with the potential for functional cure 20 Follow Up AB - 729 + veb

  21. Slide 21: AB-836 Capsid Inhibitor

    NASDAQ: ABUS www.arbutusbio.com Novel chemical series differentiated from AB - 506 and other competitor compounds in the Class II capsid inhibitor space Leverages a novel binding site within the core protein dimer - dimer interface Improved intrinsic potency with EC50 < 10 nM Active against NA resis

  22. Slide 22: AB-836: A Next Generation Capsid Inhibitor

    NASDAQ: ABUS www.arbutusbio.com AB - 836: A Next Generation Capsid Inhibitor HBV DNA / 1 o Mechanism cccDNA Formation / 2 o Mechanism Human Serum Shift Compound HepDE19 ; EC 50 μM Ϳ HBV infected PHH ; EC 50 μM Ϳ HBV infected HepG2 - NTCP - C4 ; EC 50 μM Ϳ Core I105T Mutation (EC 50 mM) HBV infected

  23. Slide 23: Next Gen RNA Destabilizer Program

    NASDAQ: ABUS www.arbutusbio.com Next Gen RNA Destabilizer Program We believe this approach offers potential for an oral HBsAg reducing agent and all oral combination therapy Continuing active research and development of a next generation small molecule Offers a novel mechanism of action to reduce HB

  24. Slide 24: Coronavirus Strategy

    NASDAQ: ABUS www.arbutusbio.com Long term commitment Pan - coronavirus focused Small Molecule Direct - Acting Antivirals Directed Effort ▪ nsp12 Viral Polymerase - nucleos (t)ides ▪ nsp5 Main Viral Protease - de novo design Screening Effort ▪ Proprietary library screening through COVID R&D consortiu

  25. Slide 25: 2021 Key Objectives

    NASDAQ: ABUS www.arbutusbio.com 2021 Key Objectives Cash balance of ~ $123M (unaudited) as Dec 31, 2020, cash runway into mid - 2022 Objective Anticipated Timing 2021 Additional data from AB - 729 90 mg single - dose in HBV DNA positive subjects 1H Additional data from AB - 729 60 mg multi - dose (4

Arbutus Biopharma — Investor Presentation (January 2021) on 6ix